FcγRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion

BACKGROUND: Immune compromised mice are increasingly used for the preclinical development of monoclonal antibodies (mAb). Most common are non-obese diabetic (NOD) severe combined immunodeficient (SCID) and their derivatives such as NOD SCID interleukin-2 γ-/- (NSG), which are attractive hosts for pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Oldham, Robert J, Mockridge, C Ian, James, Sonya, Duriez, Patrick J, Chan, H T Claude, Cox, Kerry L, Pitic, Vicentiu A, Glennie, Martin J, Cragg, Mark S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304853/
https://www.ncbi.nlm.nih.gov/pubmed/32554613
http://dx.doi.org/10.1136/jitc-2020-000619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304853/
https://www.ncbi.nlm.nih.gov/pubmed/32554613
http://dx.doi.org/10.1136/jitc-2020-000619

Ejemplares similares